Why is Alivus Life falling/rising?

As of 20-Aug, Alivus Life Sciences Ltd is experiencing a slight increase in its stock price, currently at 960.10, reflecting a change of 1.5 or 0.16% upward. The stock has shown mixed performance recently, with a 1-week decline of 0.16% and a 1-month drop of 9.10%. However, today's trading activity indicates a positive trend, as the stock has outperformed its sector by 0.58%. Notably, the delivery volume has surged by 120.17% compared to the 5-day average, suggesting increased investor participation. Despite these positive indicators, the stock has underperformed over the past year with a return of -3.47%, even as profits have risen by 10.9%. The company maintains a high return on equity (ROE) of 25.32% and a low debt-to-equity ratio, which are generally favorable factors, but it trades at a premium compared to peers, indicating potential overvaluation.
In the broader market context, the Sensex has shown a positive return of 1.64% over the past week, contrasting with Alivus's slight decline during the same period. While the stock's recent performance has been lackluster compared to the benchmark, the significant increase in delivery volume and the company's strong management efficiency may indicate a potential turnaround. However, the long-term growth concerns, highlighted by modest net sales growth and flat results in June, suggest that investors remain cautious. Overall, while the stock is currently rising, its longer-term performance relative to the market and its peers raises questions about sustainability.